EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives

Yi Wang, Yike Li, Zhong Liang, Yuqiao Zhang, Tong Li, Chenjun Tian, Jinyu Zhao, Boru Jin, Jie Cao, Yanyan Lin

Frontiers in Cell and Developmental Biology · 02.07.2025 · 13

DOI: 10.3389/fcell.2025.1616064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 02.07.2025. Verfasst von Yi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Gansu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma is a highly heterogeneous malignant tumor, including intrahepatic cholangiocarcinoma, hepatoportal cholangiocarcinoma and distal cholangiocarcinoma. Its incidence is increasing worldwide and currently accounts for approximately 15% of all primary liver cancers and 3% of all gastrointestinal malignancies. There is a lack of early diagnostic methods for cholangiocarcinoma, and the overall treatment effect is poor, with a 5-year survival rate of less than 25%. New biomarkers are urgently needed in clinical practice to improve the current diagnosis and treatment status. Circulating tumor DNA (ctDNA) is DNA fragments released by tumor cells, which can show tumor-specific gene mutations (such as IDH1/2, FGFR2 fusion) and epigenetic modifications (such as abnormal methylation). With the rapid development of tumor liquid biopsy technology, ctDNA has been gradually applied in solid tumors such as lung cancer and colorectal cancer due to its high sensitivity and dynamic monitoring capabilities. This review systematically introduces ctDNA technology and its progress in early screening, early diagnosis, treatment response, and prognosis monitoring of cholangiocarcinoma. In addition, this review also summarizes the challenges and limitations of current ctDNA technology and analyzes future hot research directions.

Schlagwörter

Stichwörter der Autor:innen

cholangiocarcinomacirculating tumor DNAliquid biopsyprognosis monitoringtumor-informed ctDNA

Autor:innen und Institutionen

  • The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
  • Department of Urology, The First People's Hospital of Lanzhou City, Lanzhou, China.
  • West China School of Medicine, Sichuan University, Chengdu, China.
  • Department of laboratory, The First Hospital of Lanzhou University, Lanzhou, China.
  • Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.

Förderung

  • Natural Science Foundation of Gansu Province

Zitieren

APA

Wang, Y., Li, Y., Liang, Z., Zhang, Y., Li, T., Tian, C., Zhao, J., Jin, B., Cao, J., & Lin, Y. (2025). Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives. Frontiers in Cell and Developmental Biology, 13. https://doi.org/10.3389/fcell.2025.1616064

Vancouver

Wang Y, Li Y, Liang Z, Zhang Y, Li T, Tian C, et al. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives. Frontiers in Cell and Developmental Biology. 2025;13. doi:10.3389/fcell.2025.1616064

BibTeX
@article{Wang2025,
  author = {Wang, Yi and Li, Yike and Liang, Zhong and Zhang, Yuqiao and Li, Tong and Tian, Chenjun and Zhao, Jinyu and Jin, Boru and Cao, Jie and Lin, Yanyan},
  title = {Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2025},
  volume = {13},
  doi = {10.3389/fcell.2025.1616064}
}
Kostenlos starten →